Home >> Blog >> Accent Microcell Ltd. IPO : Review, Valuation, Date & GMP
Accent Microcell Ltd. IPO : Review, Valuation, Date & GMP
Table of Contents
- Accent Microcell Limited IPO - Complete Overview
- What does the company do?
- Accent Microcell Limited IPO Overview
- Company Financial
- The Objective of the Issue
- Promoters and Management of Accent Microcell Limited IPO
- Accent Microcell Limited IPO Lead Managers
- Peers of Accent Microcell Limited IPO
- IPO's Valuations
- Dividend Policy
- IPO's Strengths
- IPO's Weaknesses
- IPO GMP Today
- Conclusion
Accent Microcell Limited IPO - Complete Overview
Established in 2001 by a dynamic group of experienced individuals in the pharmaceutical field, Accent Microcell has become a respected name in the industry. The company is well-known for its expertise in manufacturing and supplying excipients and their derivative products.
Serving customers in over 45 countries, including the US, Canada, Germany, the UK, Japan, and China, Accent Microcell Ltd specializes in Microcrystalline Cellulose (MCC), a fine white powder derived from refined wood pulp. The company manufactures 22 different types of MCC with varying particle sizes, catering to the pharmaceuticals, nutraceuticals, food, and cosmetics industries.
The global pharmaceutical industry is substantial, valued at approximately $209.85 billion in 2021 and expected to reach $352.98 billion by 2030, with an annual growth rate of 5.9%.
What does the company do?
Turning their focus to the pharmaceutical sector in India, it stands as the third-largest producer by volume. Over the past nine years, it has demonstrated a growth rate of 9.43% annually. Accent Microcell Ltd, a key player in this industry for 11 years, is recognized for producing high-quality materials used in pharmaceuticals, food, cosmetics, and more.
Accent Microcell Limited IPO Overview
The Accent Microcell Limited IPO date is slated to be open for subscription from December 8, 2023, to December 12, 2023. This NSE SME IPO follows a Book Built Issue IPO.
The Accent Microcell Limited IPO price is fixed at Rs.133 to Rs.140 per share. The upcoming NSE SME will be listed on December 15, 2023.
The total issue size of this IPO amounts to Rs.78.40 CR. Within this total issue, 35% is issued to retail investors.
Accent Microcell Limited IPO timetable (Tentative)
Events |
Date |
IPO Opening Date |
8 December 2023 |
IPO Closing Date |
12 December 2023 |
IPO Allotment Date |
13 December 2023 |
Refund initiation |
14 December 2023 |
IPO Listing Date |
15 December 2023 |
Accent Microcell Limited IPO Details
IPO opening & closing date |
8 December to 12 December 2023 |
Face value |
Rs.10 per share |
Issue Price |
Rs.133 to Rs.140 per share |
Lot Size |
1000 Shares |
Price of 1 lot |
Rs.1,40,000 |
Total Issue Size |
5,600,000 shares (aggregating up to Rs.78.40 Cr) |
Fresh issue |
5,600,000 shares (aggregating up to Rs.78.40 Cr) |
Listing at |
NSE SME |
Issue Type |
Book Built Issue IPO |
Registrar |
Kfin Technologies Limited |
Accent Microcell Limited IPO Lot Details
Application |
Lots |
Shares |
Minimum Lot Investment (Retail) |
1 lot |
1000 |
Maximum Lot Investment (Retail) |
1 lot |
1000 |
Minimum Lot Investment (HNI) |
2 lot |
2000 |
Accent Microcell Limited IPO Reservation
QIB Shares Offered |
Not more than 50% |
Retail Shares Offered |
Not less than 35% |
HNI Shares Offered |
Not less than 15% |
Company Financial
As of June 30 in FY 23, Accent Microcell Limited has seen significant financial growth, with Total Assets at Rs. 12,214.89 lakhs, Total Revenue at Rs. 5,992.95 lakhs, and Profit After Tax (PAT) at Rs. 705.53 lakhs. This reflects a notable increase from FY 22, indicating positive momentum and financial strength.
(Amount in Lakhs)
Period |
Jun 30 FY 23 |
FY 23 |
FY 22 |
Total Assets |
12,214.89 |
11,409.69 |
9,461.04 |
Total Revenue |
5,992.95 |
20,696.75 |
16,753.97 |
PAT |
705.53 |
1,301.02 |
589.31 |
Net worth |
5,125.44 |
4,419.91 |
3,209.32 |
Reserve & Surplus |
3,831.14 |
3,125.61 |
1,919.02 |
Total Borrowings |
2,105.73 |
2,278.23 |
2,409.53 |
REVENUE-DISTRIBUTION PRODUCT WISE
As of June 30 in FY 23, Accent Microcell Limited's sales distribution by product shows that about 73% comes from Pharmaceuticals, 11% from Nutraceuticals, and 17% from Food. In the previous fiscal year (FY 22), the percentages were roughly the same, and in the current FY 23, they remain consistent.
( in % age)
Particulars |
Jun 30 F.Y. 23 |
F.Y. 23 |
F.Y. 22 |
Pharmaceuticals |
72.74 |
71.86 |
72.60 |
Nutraceuticals |
10.52 |
10.47 |
9.62 |
Food |
16.73 |
17.67 |
17.78 |
Total |
100.00 |
100.00 |
100.00 |
REVENUE-DISTRIBUTION GEOGRAPHICAL WISE
As of June 30 in FY 23, Companies sales are divided geographically, with 38.42% in Domestic Sales and 61.58% in Export Sales. In the previous fiscal year (F.Y. 22), Domestic Sales were 34.68%, and Export Sales were 65.32%. In the current FY 23, Domestic Sales are 36.58%, and Export Sales are 63.42%.
( in % age)
State/ Country |
Jun 30 F.Y. 23 |
F.Y. 23 |
F.Y. 22 |
(1)Domestic Sales |
38.42 |
36.58 |
34.68 |
(2)Export Sales |
61.58 |
63.42 |
65.32 |
Total 1+2 |
100.00 |
100.00 |
100.00 |
Revenue By operations
As of June 30 in FY 23, Revenue from Operations constitutes approximately 98.1% of Accent Microcell Limited's total Revenue from Operations. Other Operating Income makes up the remaining approximately 1.9%.
(Amount in Lakhs)
Particulars |
JUN 30 - FY 23 |
FY 23 |
FY 22 |
Revenue from operations |
5,880.56 |
20,418.76 |
16,571.13 |
Other Operating Income |
112.39 |
277.98 |
182.84 |
Total Revenue from operations |
5,992.95 |
20,696.75 |
16,753.97 |
The Objective of the Issue
The company intends to use the net proceeds for the following objectives.
-
Building a factory in Navagam Kheda to make Croscarmellose Sodium ("CCS"), Sodium Starch Glycolate, and Carboxymethylcellulose (CMC).
-
Handling regular company costs.
Promoters and Management of Accent Microcell Limited IPO
1. Mr. Vasant Vadilal Patel
2. Mr. Ghanshyam Arjanbhai Patel
3. Mr. Nitin Jasvantbhai Patel
4. Mr. Vinodbhai Manibhai Patel
Pre-issue Promoter Shareholding |
73.13% |
Post-issue Promoter Shareholding |
53.67% |
Accent Microcell Limited IPO Lead Managers
-
Corporate Capitalventures Pvt Ltd
Peers of Accent Microcell Limited IPO
Accent Microcell Limited has a face value of Rs.10 per share, a Price-to-Earnings (P/E) ratio of 13.92, and Earnings Per Share (EPS) of Rs.10.06. While it’s peer Sigachi Industries Limited has a face value of Rs.10 per share, a P/E ratio of 16.70, and an EPS of Rs.13.52.
Name of the Company |
Face value (Rs. per share) |
P/ E |
EPS (Basic) (Rs.) |
Accent Microcell Limited |
10 |
13.92 |
10.06 |
Sigachi Industries Limited |
10 |
16.70 |
13.52 |
IPO's Valuations
To evaluate the IPO's valuation, we can utilize the information presented in the company's RHP and DRHP. Accent Microcell Limited IPO is fixed at Rs.133 to Rs. 140 per share, with an EPS of Rs.10.06. Based on the issue price the company's P/E ratio is calculated at 13.92.
Dividend Policy
The company's dividend policy can change based on profits, plans, and economic conditions. While they paid dividends of Rs.103.22 in 2022 and Rs.103.54 in 2023, it doesn't guarantee future dividends, and there's no certainty about dividends on Equity Shares going forward.
IPO's Strengths
-
Global presence in 45+ countries.
-
Specialization in Microcrystalline Cellulose (MCC) with a diverse product range.
-
Positioned in India's growing pharmaceutical sector.
-
Diversified revenue across pharmaceuticals, nutraceuticals, and food.
IPO's Weaknesses
-
Reliance on pharmaceutical sector revenue.
-
Exposure to international market uncertainties.
-
Post-issue reduction in promoter shareholding.
IPO GMP Today
The latest Grey Market Premium (GMP) for Accent Microcell SME IPO is Rs.202
Conclusion
In summary, Accent Microcell Limited's IPO looks promising with its expertise, global reach, and diverse product line. The planned expansion is a positive sign. However, investors should be cautious about the reliance on the pharmaceutical sector and international markets. The Grey Market Premium of Rs.120 indicates early interest, but thorough research is essential before making investment decisions.
You can follow MUKUL AGRAWAL for the latest IPO news and reviews. You can connect with us on social media platforms like Twitter, Facebook, and Instagram. You can also subscribe to our YouTube channel for the latest stock market videos.
Finowings IPO Analysis
Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.
You must consult your financial advisor before making any financial decisions.
To Apply for the IPO, Click Here.
To Read the Prospectus of the Company Click Here to Download the DRHP.
Thank You for reading this blog.
Hope you loved the IPO analysis.
Please Comment Below with your feedback because Your feedback motivates us to deliver more such content.
Follow MUKUL AGRAWAL for the latest IPO news and reviews. You can connect with us on social media platforms like Twitter, Facebook, and Instagram. You can also subscribe to our YouTube Channel for the latest videos of the stock market.
Frequently Asked Questions
As of the last update on December 5th, 2023, the GMP is Rs.120.
The IPO is expected to be listed on NSE SME on December 15, 2023.
The IPO shares are priced at Rs.133 to Rs.140 per share.
The IPO is open for subscription from December 8, 2023, to December 12, 2023.